Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SETOM: FMT for Overweight and Obese T2DM
NCT05253768Phase 2Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fecal microbiome transplant in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Percentage of change in weight compared with baseline at 12 weeks. Started Mar 2024; status: recruiting.
02
Drugs
fecal microbiome transplant
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05253768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253768.